NASDAQ:EIDX Eidos Therapeutics (EIDX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free EIDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$122.21▼$122.2150-Day Range$120.98▼$128.5152-Week Range$28.39▼$132.54VolumeN/AAverage Volume128,113 shsMarket Capitalization$4.75 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Eidos Therapeutics alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Eidos Therapeutics Stock (NASDAQ:EIDX)Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. EIDX Stock News HeadlinesFebruary 3, 2024 | thestreet.comThe Anglo File: Game Over for Board Lapses at EidosJanuary 31, 2024 | msn.comDeus Ex game canceled as nearly 100 Eidos-Montreal staff laid offApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.January 31, 2024 | msn.comEmbracer Group reportedly cancels unannounced Deus Ex game, lays off staff at Eidos MontrealJanuary 31, 2024 | msn.comEmbracer lays off 97 Eidos employees and cancels new Deus Ex gameJuly 16, 2023 | investing.comEidos Therapeutics Inc (EIDX)June 27, 2023 | finance.yahoo.comVTGN - Vistagen Therapeutics, Inc.April 7, 2023 | msn.comEidos' Guardians of the Galaxy Can Still Ride the Wave of Volume 3's May ReleaseApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 24, 2023 | benzinga.comCara Therapeutics Stock (NASDAQ:CARA), Quotes and News SummaryDecember 28, 2022 | finanznachrichten.deAdvanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private PlacementJuly 28, 2022 | msn.comSony Eyeing Square Enix Tokyo Purchase Months After Crystal Dynamics, Eidos Montreal SaleJuly 26, 2022 | msn.comSony wants to buy Square Enix Tokyo claims Eidos-Montréal founderMay 2, 2022 | msn.comThe Eidos games that could be revived with the Embracer acquisitionMay 2, 2022 | venturebeat.comEmbracer agrees to buy Crystal Dynamics, Eidos-Montréal, Square Enix Montréal, and their IPOctober 8, 2021 | msn.comVideo-game studio Eidos-Montreal is switching to a 4-day work week for its staff, cutting weekly hours from 40 to 32 while keeping salaries the sameSeptember 22, 2021 | news.yahoo.comEidos-Montréal gambles with entry into "Guardians of the Galaxy" franchiseJuly 24, 2021 | nasdaq.comEidos Therapeutics, Inc. Common Stock (EIDX)See More Headlines Receive EIDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/29/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EIDX CUSIPN/A CIKN/A Webwww.eidostx.com Phone415-887-1471FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.21% Return on Assets-53.04% Debt Debt-to-Equity Ratio0.14 Current Ratio11.10 Quick Ratio11.10 Sales & Book Value Annual Sales$26.69 million Price / Sales177.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book26.74Miscellaneous Outstanding Shares38,873,000Free FloatN/AMarket Cap$4.75 billion OptionableNot Optionable Beta-0.16 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Neil Kumar (Age 42)CEO & Director Comp: $247.68kDr. Uma Sinha (Age 64)Chief Scientific Officer & Director Comp: $533.4kDr. Cameron Turtle DPHIL (Age 31)Ph.D., Chief Bus. Officer Comp: $578.4kDr. Jonathan C. Fox FACC (Age 64)M.D., Ph.D., Pres & Chief Medical Officer Dr. Isabella Graef M.D. (Age 56)Co-Founder & Board Advisor Dr. Mamoun Alhamadsheh Ph.D.Pharm.D., Co-FounderMr. Franco Valle (Age 40)Sr. VP of Fin., Principal Accounting Officer & Sec. Mr. Matt OuttenChief Commercial OfficerDr. Hoyoung Huh (Age 52)Consultant More ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNBridgeBio PharmaNASDAQ:BBIOMadrigal PharmaceuticalsNASDAQ:MDGLNuvalentNASDAQ:NUVLAlpine Immune SciencesNASDAQ:ALPNView All Competitors EIDX Stock Analysis - Frequently Asked Questions How were Eidos Therapeutics' earnings last quarter? Eidos Therapeutics, Inc. (NASDAQ:EIDX) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.08. The firm had revenue of $0.13 million for the quarter. What other stocks do shareholders of Eidos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM). When did Eidos Therapeutics IPO? Eidos Therapeutics (EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager. This page (NASDAQ:EIDX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eidos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
